391 related articles for article (PubMed ID: 26046793)
1. Identification of TAX2 peptide as a new unpredicted anti-cancer agent.
Jeanne A; Sick E; Devy J; Floquet N; Belloy N; Theret L; Boulagnon-Rombi C; Diebold MD; Dauchez M; Martiny L; Schneider C; Dedieu S
Oncotarget; 2015 Jul; 6(20):17981-8000. PubMed ID: 26046793
[TBL] [Abstract][Full Text] [Related]
2. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide.
Jeanne A; Boulagnon-Rombi C; Devy J; Théret L; Fichel C; Bouland N; Diebold MD; Martiny L; Schneider C; Dedieu S
Clin Exp Metastasis; 2016 Oct; 33(7):637-49. PubMed ID: 27349907
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma.
Jeanne A; Martiny L; Dedieu S
Pediatr Res; 2017 Mar; 81(3):480-488. PubMed ID: 27842053
[TBL] [Abstract][Full Text] [Related]
4. Towards the Therapeutic Use of Thrombospondin 1/CD47 Targeting TAX2 Peptide as an Antithrombotic Agent.
Jeanne A; Sarazin T; Charlé M; Kawecki C; Kauskot A; Hedtke T; Schmelzer CEH; Martiny L; Maurice P; Dedieu S
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e1-e17. PubMed ID: 33232198
[TBL] [Abstract][Full Text] [Related]
5. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
6. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
7. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis.
Choi HS; Lee K; Kim MK; Lee KM; Shin YC; Cho SG; Ko SG
Oncotarget; 2016 Apr; 7(16):21775-85. PubMed ID: 26967562
[TBL] [Abstract][Full Text] [Related]
8. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
[TBL] [Abstract][Full Text] [Related]
9. Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis.
Saraswati S; Kanaujia PK; Kumar S; Kumar R; Alhaider AA
Mol Cancer; 2013 Jul; 12():82. PubMed ID: 23895055
[TBL] [Abstract][Full Text] [Related]
10. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
11. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
[TBL] [Abstract][Full Text] [Related]
12. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model.
Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM
Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.
Streit M; Velasco P; Brown LF; Skobe M; Richard L; Riccardi L; Lawler J; Detmar M
Am J Pathol; 1999 Aug; 155(2):441-52. PubMed ID: 10433937
[TBL] [Abstract][Full Text] [Related]
15. Context dependent role of the CD36--thrombospondin--histidine-rich glycoprotein axis in tumor angiogenesis and growth.
Hale JS; Li M; Sinyuk M; Jahnen-Dechent W; Lathia JD; Silverstein RL
PLoS One; 2012; 7(7):e40033. PubMed ID: 22808089
[TBL] [Abstract][Full Text] [Related]
16. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
de Aguiar RB; Parise CB; Souza CR; Braggion C; Quintilio W; Moro AM; Navarro Marques FL; Buchpiguel CA; Chammas R; de Moraes JZ
Cancer Lett; 2016 Feb; 371(2):151-60. PubMed ID: 26655277
[TBL] [Abstract][Full Text] [Related]
17. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
18. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
[TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
20. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
